Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.48 $56,448 - $106,176
-11,200 Reduced 47.38%
12,439 $95,000
Q1 2022

May 16, 2022

BUY
$7.09 - $89.45 $167,600 - $2.11 Million
23,639 New
23,639 $182,000

Others Institutions Holding KOD

About Kodiak Sciences Inc.


  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $392M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.